Ark gains on hopes for cancer drug

Ark Therapeutics, the gene therapy group, gave the beleaguered UK biotech industry a shot in the arm yesterday when it said that the third phase trial of its brain cancer treatment, Cerepro, has shown good initial results and that it now expects to be able to market the drug by next year.

The company's shares rocketed on the news closing the day up 69 per cent at 80.25p. Ark had earlier said that the topline results of the tests showed that patients using the treatment were on average surviving 42 days longer than people not using Cerepro.

The results come from tests on 183 patients with the company expected to give details of another 53 cases early next year, after which it will apply to European regulators for a licence to sell the drug.

Ibraheem Mahmood, an analyst at Investec, said that while yesterday's news was encouraging, the real tonic for the group is that the positive tests validate Ark's gene based technology and that should lead to interest from some of the pharmaceutical giants. "While the news is certainly good, it is really only a by-product," he said. "Cerepro will be worth between about $500m and $1bn, but it is the first time that the technology has been shown to work and that makes it appealing to buyers."

The news will also be welcomed by the wider UK biotech market, which has a poor record of converting potential drugs in trial into commercial successes. In recent weeks two other groups, Alizyme and Oxford Biomedica, have disclosed pivotal phase three failures, which sent the share price of both companies crashing.

However, the news on Cerepro was not greeted with universal praise. KBC analyst Paul Cuddon pointed out that Cerepro will need to compete against existing medicines. "In order for the trial to be considered a success, and for the company to claim they have a blockbuster, it has to show that it is better than what is already out there, and these trials do not show that," he said. "Ark needed to show that Cerepro is more effective than Temador [another brain cancer treatment] and they have not done that. I still have major concerns."

Mr Mahmood countered that Temador, which had annual sales of $861m last year, has side effects akin to the symptoms suffered by AIDS sufferers, giving patients a poor quality of life.

Independent Comment
blog comments powered by Disqus
Career Services

Day In a Page

How an abortion divided America

How an abortion divided America

Single mother who took a pill to end her pregnancy is now fighting a landmark prosecution in a conservative state
Can you master a language in a weekend?

Can you master a language in a weekend?

Ed Cooke insists he can use his techniques as a memory expert to help novices learn even the hardest tongues.
The 10 best heaters

The 10 best heaters

From the DeLonghi Retro Fan Heater to the Dimplex MicroFire
Coming soon to a shelf near you: The publishing industry has gone mad for film-style trailers

Coming soon to a shelf near you

The publishing industry has gone mad for film-style trailers
Mad, bad and delightful to know: How Lord Byron became a cultural superstar

How Lord Byron became a cultural superstar

As the poet takes centre stage in the West End, Boyd Tonkin looks into the life of the outspoken champion of the poor
Did they all live happily ever after? That's up to you...

Did they all live happily ever after? That's up to you...

New digital novel will overturn centuries of literary tradition by allowing readers to choose how they would like story to end
How to look good for less – Primark in copycat row

How to look good for less – Primark in copycat row

With London Fashion Week starting tomorrow, designers are closeted in studios putting finishing touches to their collections
James Lawton: Arsène and Arsenal are living in the past

James Lawton

Arsène and Arsenal are living in the past
How Docherty's resurgent Reds beat Dutch greats

How Docherty's resurgent Reds beat Dutch greats

United have met Ajax only once before in Europe, in 1976. The key performers recall an electric occasion
Civil war at Ajax

Civil war at Ajax

A rift between two club legends has torn the Dutch giants apart
Lewis Moody: For an idea of where England are headed, look at Wales now

Lewis Moody column

For an idea of where England are headed, look at Wales now
Geoff Toovey: Little gem with huge incentive to become king of the world

Geoff Toovey interview

Little gem with huge incentive to become king of the world
Picture preview: Portrait of London

Portrait of London

Picture preview
No secularism please, we're British

No secularism please, we're British

Arguments about the role of religion in national life have recently acquired a new urgency
Harold Tillman: 'Chinese tourists can save the high street – if we let them'

Harold Tillman interview

'Chinese tourists can save the high street – if we let them'